8. Assessment and Reflective Practice
Pedagogy: This lesson uses integrative case-based reasoning — five clinical scenarios spanning the full course content, testing the learner's ability to synthesise knowledge across chapters into real-world management plans.
Learning Objectives
- Apply integrated knowledge from all chapters to complex clinical scenarios
- Demonstrate shared decision-making in menopause consultations
- Construct multi-domain management plans incorporating HRT, CVD prevention, lifestyle, and specialist referral
- Recognise the limits of primary care management and appropriate referral triggers
Key Facts
Five Integrated Clinical Scenarios
The following cases draw on content from across the entire course. Work through each scenario, formulating your management plan before revealing the model answer. Consider the patient's priorities, risk factors, and the applicable guideline recommendations.
Clinical Pearl Complex menopause management requires synthesis across multiple domains: symptoms, CVD risk, bone health, breast cancer risk, mental health, and patient preference. No single guideline covers everything — the skill is in integration.
Clinical Pearl The best menopause consultations balance evidence with empathy. A technically perfect HRT prescription is worthless if the patient doesn't trust you enough to take it.
Case-Based Examples
Case 1: Case A: 48-year-old with VMS, anxiety, and family history of breast cancer
Presentation: A 48-year-old presents with moderate VMS (6/day), significant anxiety, poor sleep, and a first-degree family history of breast cancer (mother, aged 62). She is perimenopausal (irregular periods for 12 months). BMI 27. BP 128/82. She is frightened of HRT because of the breast cancer link.
Question: Construct a comprehensive management plan addressing all domains.
Model Answer: (1) Symptom assessment: MRS to capture full profile. (2) Breast cancer counselling: use NICE absolute risk data — family history (one first-degree relative over 50) confers modest additional risk. Combined HRT for 5 years adds ~20 cases per 1,000 over 20 years. Context: obesity and alcohol carry comparable risk. (3) If she accepts HRT: sequential transdermal oestradiol + micronised progesterone (lower breast risk than synthetic). (4) If she declines HRT: fezolinetant for VMS (NICE TA1143); menopause-specific CBT for anxiety, VMS impact, and sleep (NICE NG23). (5) CVD: QRISK3, fasting lipids, HbA1c. (6) Lifestyle: exercise 150 min/week, Mediterranean diet, alcohol reduction, sleep hygiene. (7) Psychological: consider GAD-7/PHQ-9 — if anxiety is primary, CBT or SSRI may be needed independently. (8) Review at 3 months.
Case 2: Case B: 38-year-old with suspected POI post-chemotherapy requesting fertility
Presentation: A 38-year-old, nulliparous, underwent chemotherapy for lymphoma 2 years ago. Periods stopped during treatment and have not returned. FSH 48 IU/L (confirmed on two samples). She is desperate to conceive and also experiencing severe VMS, joint pain, and low mood.
Question: Design a multi-disciplinary management plan.
Model Answer: (1) Confirm POI: FSH >25 IU/L x2 — confirmed. (2) Fertility: urgent referral to reproductive medicine — donor oocyte IVF may be needed, but spontaneous ovulation occurs in ~25% of POI; she should not lose hope. (3) HRT: start immediately regardless of fertility plans — transdermal oestradiol (standard-to-high dose given age 38) + micronised progesterone sequential. HRT is NOT a contraceptive. (4) Bone: DEXA baseline (chemotherapy + oestrogen deficiency = high risk). (5) CVD: comprehensive assessment (POI confers 60% increased CVD risk if untreated). (6) Psychological: referral for psychological support — grief, fertility loss, cancer survivorship. PHQ-9/GAD-7. (7) Additional investigations: karyotype, FMR1 (if not already done — relevant to potential genetic causes and implications for offspring). (8) Multidisciplinary team: menopause specialist + fertility specialist + oncologist + psychologist. Continue HRT until at least age 51. (9) Review at 3 months for HRT optimisation.
Self-Assessment Questions
PLAB/MLA Integrated case: route selection
A 52-year-old with BMI 33, migraine with aura, and moderate VMS requests HRT. Which is most appropriate?
A. Oral oestradiol 2mg + MPA
B. Transdermal oestradiol + micronised progesterone
C. Combined oral contraceptive pill
D. Tibolone
Answer: B. BMI >30 AND migraine with aura both mandate transdermal oestrogen. Micronised progesterone has lower VTE/breast risk than MPA.
MRCGP Integrated case: stopping HRT safely
A 58-year-old on continuous combined HRT for 7 years wants to stop. She has controlled hypertension and BMI 30. How do you advise her?
A. Stop immediately
B. Calculate FRAX, check BP/lipids/HbA1c, counsel about VMS recurrence (up to 87%), offer gradual dose reduction, and plan bone protection if indicated
C. She must continue HRT indefinitely
D. Switch to oestrogen-only therapy
Answer: B. Multi-domain approach: assess bone protection needs (FRAX), update cardiovascular assessment, counsel about VMS recurrence, gradual reduction. Bisphosphonate if bone risk warrants.
Professor Integrated case: precision menopause in clinical practice
Evaluate whether the precision menopause framework (Ravindran and Varma, 2026) could be implemented in routine UK primary care given current workforce, time, and QOF constraints.
A. Implementation is straightforward
B. The framework is clinically sound but faces implementation barriers: GP consultation time (~10 min), no specific QOF menopause indicators, variable clinician confidence, and lack of integrated clinical decision support; however, overlap with CVD prevention QOF domains creates a pragmatic entry point
C. The framework is irrelevant to primary care
D. QOF already covers menopause comprehensively
Answer: B. The precision menopause pathway adds QRISK3, fasting lipids, HbA1c, and waist circumference to the standard menopause consultation. This overlaps substantially with CVD prevention QOF indicators (worth £198 million from 2025/26), creating a 'twofer' incentive. Barriers: typical GP appointments are 10-15 minutes; the full assessment may need a dedicated longer appointment or nurse-led pre-assessment; GP menopause training is variable (BMS certification is voluntary). A pragmatic implementation model: nurse-led cardiometabolic pre-assessment + GP-led HRT decision + annual nurse-led review. Clinical decision support via practice templates would standardise delivery.
Take-Away Messages
- Complex menopause management requires synthesis across symptoms, CVD risk, bone health, breast cancer risk, and patient preference
- Use the NICE absolute risk data and discussion aid for shared decision-making about HRT
- POI: start HRT immediately regardless of symptoms; refer to MDT; continue until at least age 51
- The precision menopause framework combines symptom relief with rigorous cardiometabolic assessment
- Document shared decisions clearly — good menopause care is both clinically excellent and medicolegally sound